CureVac Retained Earnings vs Net Receivables Analysis
CVAC Stock | USD 2.66 0.10 3.91% |
CureVac NV financial indicator trend analysis is way more than just evaluating CureVac NV prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether CureVac NV is a good investment. Please check the relationship between CureVac NV Retained Earnings and its Net Receivables accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in CureVac NV. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. For information on how to trade CureVac Stock refer to our How to Trade CureVac Stock guide.
Retained Earnings vs Net Receivables
Retained Earnings vs Net Receivables Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of CureVac NV Retained Earnings account and Net Receivables. At this time, the significance of the direction appears to have significant contrarian relationship.
The correlation between CureVac NV's Retained Earnings and Net Receivables is -0.47. Overlapping area represents the amount of variation of Retained Earnings that can explain the historical movement of Net Receivables in the same time period over historical financial statements of CureVac NV, assuming nothing else is changed. The correlation between historical values of CureVac NV's Retained Earnings and Net Receivables is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Retained Earnings of CureVac NV are associated (or correlated) with its Net Receivables. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Net Receivables has no effect on the direction of Retained Earnings i.e., CureVac NV's Retained Earnings and Net Receivables go up and down completely randomly.
Correlation Coefficient | -0.47 |
Relationship Direction | Negative |
Relationship Strength | Very Weak |
Retained Earnings
The cumulative amount of net income that a company retains for reinvestment in its operations, rather than distributing it to shareholders as dividends.Net Receivables
Most indicators from CureVac NV's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into CureVac NV current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in CureVac NV. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. For information on how to trade CureVac Stock refer to our How to Trade CureVac Stock guide.At present, CureVac NV's Sales General And Administrative To Revenue is projected to slightly decrease based on the last few years of reporting.
2021 | 2022 | 2023 | 2024 (projected) | Depreciation And Amortization | 35.9M | 26.2M | 23.4M | 20.3M | Interest Income | 10.1M | 4.0M | 12.9M | 13.6M |
CureVac NV fundamental ratios Correlations
Click cells to compare fundamentals
CureVac NV Account Relationship Matchups
High Positive Relationship
High Negative Relationship
CureVac NV fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 130.6M | 1.5B | 1.2B | 860.5M | 788.2M | 838.7M | |
Other Current Liab | 13.3M | 56.1M | 171.4M | 44.7M | 88.0M | 70.9M | |
Total Current Liabilities | 28.1M | 247.6M | 357.7M | 156.2M | 186.4M | 184.1M | |
Total Stockholder Equity | (42.8M) | 711.3M | 688.5M | 533.3M | 516.9M | 447.2M | |
Net Tangible Assets | (48.2M) | 697.9M | 676.2M | 501.5M | 576.7M | 407.8M | |
Property Plant And Equipment Net | 66.8M | 104.8M | 200.4M | 241.7M | 278.6M | 171.9M | |
Current Deferred Revenue | 7.5M | 158.0M | 55.8M | 36.8M | 46.3M | 56.8M | |
Net Debt | 48.5M | (1.3B) | (782.6M) | (453.7M) | (360.6M) | (378.7M) | |
Retained Earnings | (515.9M) | (645.1M) | (1.1B) | (1.3B) | (1.6B) | (1.5B) | |
Accounts Payable | 5.3M | 17.6M | 122.3M | 68.2M | 46.4M | 49.3M | |
Cash | 30.7M | 1.3B | 811.5M | 495.8M | 402.8M | 565.5M | |
Non Current Assets Total | 73.4M | 121.5M | 218.2M | 276.4M | 309.9M | 192.9M | |
Non Currrent Assets Other | 967K | 1.1M | 1.2M | 1.7M | (13.0M) | (12.4M) | |
Other Assets | 6.3M | 7.5M | 5.6M | 3.0M | 1.0 | 0.95 | |
Cash And Short Term Investments | 32.1M | 1.3B | 816.1M | 500.3M | 402.8M | 575.1M | |
Net Receivables | 17.7M | 1.8M | 53.7M | 9.0M | 17.1M | 19.5M | |
Common Stock Shares Outstanding | 186.9M | 132.2M | 186.0M | 189.1M | 220.8M | 200.0M | |
Short Term Investments | 1.5M | 2.6M | 4.6M | 4.5M | 2.7M | 2.5M | |
Liabilities And Stockholders Equity | 130.6M | 1.5B | 1.2B | 860.5M | 788.2M | 838.7M | |
Non Current Liabilities Total | 145.3M | 552.4M | 112.0M | 171.0M | 84.9M | 150.8M | |
Capital Lease Obligations | 14.1M | 55.3M | 28.9M | 42.1M | 41.8M | 33.4M | |
Inventory | 6.2M | 14.5M | 56.2M | 24.0M | 24.8M | 23.6M | |
Other Current Assets | 1.2M | 48.3M | 14.0M | 20.3M | 9.0M | 17.5M | |
Other Stockholder Equity | 493.4M | 1.4B | (5.8M) | (1.5M) | 2.1B | 2.2B | |
Total Liab | 173.4M | 800.0M | 469.8M | 327.2M | 271.3M | 391.5M | |
Deferred Long Term Liab | 966K | 1.0M | 515K | 302K | 271.8K | 258.2K | |
Net Invested Capital | 22.2M | 711.3M | 688.5M | 533.3M | 516.9M | 459.1M | |
Property Plant And Equipment Gross | 61.7M | 104.8M | 247.4M | 258.7M | 301.8M | 186.0M | |
Total Current Assets | 57.2M | 1.4B | 940.0M | 584.0M | 478.4M | 645.8M | |
Accumulated Other Comprehensive Income | 472.4M | 1.3B | 1.7B | 1.8B | 2.1B | 1.4B | |
Non Current Liabilities Other | 529K | 284K | 264K | 19K | 17.1K | 16.2K | |
Net Working Capital | 29.1M | 1.1B | 582.3M | 427.8M | 292.0M | 461.7M | |
Short Term Debt | 2.0M | 3.2M | 3.5M | 5.0M | 5.0M | 3.5M | |
Intangible Assets | 5.7M | 14.1M | 13.2M | 19.3M | 15.9M | 13.7M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether CureVac NV offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of CureVac NV's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Curevac Nv Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Curevac Nv Stock:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in CureVac NV. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. For information on how to trade CureVac Stock refer to our How to Trade CureVac Stock guide.You can also try the Global Correlations module to find global opportunities by holding instruments from different markets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of CureVac NV. If investors know CureVac will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about CureVac NV listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 0.5 | Revenue Per Share 0.294 | Quarterly Revenue Growth 0.905 | Return On Assets (0.25) | Return On Equity (0.54) |
The market value of CureVac NV is measured differently than its book value, which is the value of CureVac that is recorded on the company's balance sheet. Investors also form their own opinion of CureVac NV's value that differs from its market value or its book value, called intrinsic value, which is CureVac NV's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because CureVac NV's market value can be influenced by many factors that don't directly affect CureVac NV's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between CureVac NV's value and its price as these two are different measures arrived at by different means. Investors typically determine if CureVac NV is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, CureVac NV's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.